SEC Info - Myriad Genetics Inc - ‘10-Q’ for 9/30/96

SEC Info℠

Home

Help

Please Sign In

Myriad Genetics Inc – ‘10-Q’ for 9/30/96

As of: Friday, 11/8/96 · For: 9/30/96 · Accession #: 927016-96-1627 · File #: 0-26642

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

11/08/96  Myriad Genetics Inc               10-Q        9/30/96    7:140K                                   Donnelley R R & S… 07/FA

Quarterly Report — Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                      13     57K 
 2: EX-10.1     Patent and Technology License Agreement               15     40K 
 3: EX-10.2     Lease Agreement/Boyer Research Park                   34    109K 
 4: EX-10.3     Amendment to Lease Agreement                           4     14K 
 5: EX-10.4     Letter Agreement Dated 03/04/96                        3      9K 
 6: EX-11.1     Statement Re Comp of Net Loss Per Share                1      6K 
 7: EX-27       Financial Data Schedule                                2      8K

10-Q — Quarterly Report
Document Table of Contents

Page	(sequential)	\|	(alphabetic)	Top
			Alternative Formats (Word, et al.) Changes in Securities Defaults Upon Senior Securities Exhibits and Reports on Form 8-K Financial Statements Legal Proceedings Management's Discussion and Analysis of Financial Condition and Results of Operations Other Information Submission of Matters to a Vote of Security Holders
1	1st Page - Filing Submission
2	Item 1. Financial Statements
7	Management's Discussion and Analysis of Financial Condition and Results of Operations
10	Item 1. Legal Proceedings
"	Item 2. Changes in Securities
"	Item 3. Defaults Upon Senior Securities
"	Item 4. Submission of Matters to a Vote of Security Holders
"	Item 5. Other Information
"	Item 6. Exhibits and Reports on Form 8-K

10-Q 1st Page of 13 TOC ↑Top Previous Next ↓Bottom Just 1st
 
UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q 

(Mark One)                                                                      
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE 
ACT OF 1934 
For the quarterly period ended September 30, 1996 
                              ------------------

[ ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES     
      EXCHANGE ACT OF 1934
  For the transition period from _______________ to ____________

Commission file number:  0-26642  
                       -------

MYRIAD GENETICS, INC. 
(Exact name of registrant as specified in its charter)

     Delaware                                     87-0494517
     --------                                     ----------
    (State or other jurisdiction            (I.R.S. Employer Identification No.)
of incorporation or organization)                                           

320 Wakara Way, Salt Lake City, UT                           84108          
----------------------------------                           -----          
(Address of principal executive offices)                    (Zip Code)          

Registrant's telephone number, including area code: (801) 584-3600  

390 Wakara Way, Salt Lake City, Utah
------------------------------------
(Former address, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was     
required to file such reports), and (2) has been subject to such filing         
requirements for the past 90 days.     Yes [X]    No [ ]                        

As of November 5, 1996, the registrant had 8,730,725 shares of common 
stock outstanding.                                                              

10-Q 2nd Page of 13 TOC 1st Previous Next ↓Bottom Just 2nd
MYRIAD GENETICS, INC. 

INDEX TO FORM 10-Q  

                                                                [Download Table]

                                                                  Page
                                                                  ----
                         PART I - Financial Information               
                                                                      
Item 1.     Financial Statements.                                     

            Condensed Consolidated Balance Sheet as of                
            September 30, 1996 and June 30,  1996                   3 

            Condensed Consolidated Statements of Operations for       
            the three months ended September 30, 1996 and 1995      4 

            Condensed Consolidated Statements of Cash Flows for       
            the three months ended September 30, 1996 and 1995      5 

            Notes to Condensed Consolidated Financial Statements    6 

Item 2.     Management's Discussion and Analysis of Financial         
            Condition and Results of Operations                     7 

                          PART II - Other Information                 

Item 1.     Legal Proceedings                                      10 

Item 2.     Changes in Securities                                  10 

Item 3.     Defaults Upon Senior Securities                        10 

Item 4.     Submission of Matters to a Vote of Security Holders    10 

Item 5.     Other Information                                      10 

Item 6.     Exhibits and Reports on Form 8-K                       10 

SIGNATURE(S)                                                       12 

2 

10-Q 3rd Page of 13 TOC 1st Previous Next ↓Bottom Just 3rd
MYRIAD GENETICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS 

                                                                [Download Table]

                                                Sept. 30, 1996                 
                                                  (Unaudited)    June 30, 1996 
                                               ---------------- ---------------
                       Assets                                                  
                       ------                                                  
                                                                               
Current assets:                                                                

  Cash and cash equivalents                       $ 14,844,580    $ 13,235,680 

  Marketable investment securities                  37,202,471      37,212,454 

  Non trade receivables                                 16,987          79,066 

  Prepaid expenses                                      96,478          88,423 
                                               ---------------  -------------- 
          Total current assets                      52,160,516      50,615,623 
                                               ---------------  -------------- 
Equipment and leasehold improvements:                                          

  Equipment                                         10,682,763       9,097,484 

  Leasehold improvements                               893,224         863,306 

  Construction in progress                             810,108         810,108 
                                               ---------------  -------------- 
                                                    12,386,095      10,770,898 

  Less accumulated depreciation and                                            
   amortization                                      1,739,501       1,375,366 
                                               ---------------  -------------- 
          Net equipment and leasehold                                          
           improvements                             10,646,594       9,395,532 

Long-term marketable investment securities          14,781,997      19,554,646 

Other assets                                            41,668          41,696 
                                               ---------------  -------------- 
                                                  $ 77,630,775    $ 79,607,497 
                                               ===============  ============== 

       Liabilities and Stockholders' Equity                                    
       ------------------------------------                                    

Current liabilities:                                                           

  Accounts payable                                $  2,498,770    $  2,193,285 

  Accrued liabilities                                  943,145         786,791 

  Deferred revenue                                   5,905,595       5,661,376 

  Current portion of notes payable                     316,860         308,658 
                                               ---------------  -------------- 
          Total current liabilities                  9,664,370       8,950,110 
                                               ---------------  -------------- 
Notes payable, less current portion                    389,252         471,640 

Stockholders' equity                                                           

  Common stock, $0.01 par value, 15,000,000                                    
   shares authorized; issued and outstanding                                   
   8,726,498 shares on September 30, 1996 and                                  
   8,702,215 shares on June 30, 1996                    87,265          87,022 

  Additional paid-in capital                        87,040,930      87,015,215 

 Fair value adjustment on available-for-sale                                   
  marketable investment securities                      (4,971)        (67,865)

  Deferred compensation                             (1,774,880)     (1,907,513)

  Accumulated deficit                              (17,771,191)    (14,941,112)
                                               ---------------  -------------- 
          Net stockholders' equity                  67,577,153      70,185,747 
                                               ---------------  -------------- 
                                                  $ 77,630,775    $ 79,607,497 
                                               ===============  ============== 

See accompanying notes to condensed consolidated financial statements.

3 

10-Q 4th Page of 13 TOC 1st Previous Next ↓Bottom Just 4th
MYRIAD GENETICS, INC. AND SUBSIDIARY  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 

                                                                [Download Table]


                                                      Three Months Ended       
                                                      ------------------       
                                               Sept. 30, 1996   Sept. 30, 1995 
                                                 (Unaudited)      (Unaudited)  
                                               ---------------  ---------------
                                                                               
Research revenue                                 $  2,195,781     $  1,012,900 
Expenses:                                                                      
  Research and development expense                  4,094,743        2,381,159 
  Selling, general and administrative expense       1,759,959          408,186 
                                               ---------------  ---------------
          Total expenses                            5,854,702        2,789,345 
                                               ---------------  ---------------
          Operating loss                           (3,658,921)      (1,776,445)

Other income (expense):                                                        
  Interest income                                     848,494          275,223 
  Interest expense                                    (19,652)         (27,045)
  Loss on sale of fixed assets                              -          (74,636)
                                               ---------------  ---------------
                                                      828,842          173,542 
                                               ---------------  ---------------
          Net loss                                ($2,830,079)     ($1,602,903)
                                               ===============  ===============
Net loss per share                                     ($0.32)          ($0.32)
                                               ===============  ===============
Weighted average shares outstanding                 8,712,829        5,067,328 


See accompanying notes to condensed consolidated financial statements.

4 

10-Q 5th Page of 13 TOC 1st Previous Next ↓Bottom Just 5th
MYRIAD GENETICS, INC. AND SUBSIDIARY  
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 

                                                                [Download Table]


                                                      Three Months Ended       
                                                      ------------------       
                                               Sept. 30, 1996   Sept. 30, 1995 
                                                 (Unaudited)      (Unaudited)  
                                               ---------------  ---------------
                                                                               
Cash flows from operating activities:                                          
  Net loss                                        ($2,830,079)     ($1,602,903)
  Adjustments to reconcile net loss to net                                     
   cash used in operating activities:                                          
   Depreciation and amortization                      496,768          445,705 
   Decrease (increase) in non-trade receivables        62,079       (1,306,343)
   Increase in other assets                            (8,027)        (138,470)
   Increase (decrease) in accounts payable                                     
      and accrued expense                             461,839         (473,524)
   Increase in deferred revenue                       244,219        1,550,000 
                                               ---------------  ---------------
      Net cash used in operating activities        (1,573,201)      (1,525,535)
                                               ---------------  ---------------
Cash flows from investing activities:                                          
  Capital expenditures                             (1,615,197)        (460,705)
  Net change in marketable investment                                          
   securities                                       4,845,526      (12,638,301)
                                               ---------------  ---------------
      Net cash provided by (used in)                                           
       investing activities                         3,230,329      (13,099,006)
                                               ---------------  ---------------
Cash flows from financing activities:                                          
  Net payments of notes payable                       (74,186)         (66,793)
  Net proceeds from issuance of common stock           25,958                - 
  Net proceeds from issuance of preferred stock             -        9,982,723 
                                               ---------------  ---------------
      Net cash (used in) provided by                                           
       financing activities                           (48,228)       9,915,930 
                                               ---------------  ---------------
Net increase (decrease) in cash and cash                                       
 equivalents                                        1,608,900       (4,708,611)
Cash and cash equivalents at beginning of                                      
 period                                            13,235,680       11,885,736 
                                               ---------------  ---------------
Cash and cash equivalents at end of period       $ 14,844,580     $  7,177,125 
                                               ===============  ===============


See accompanying notes to condensed consolidated financial statements.

5 

10-Q 6th Page of 13 TOC 1st Previous Next ↓Bottom Just 6th
MYRIAD GENETICS, INC. AND SUBSIDIARY  
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS  

(1)       Basis of Presentation                                                 

          The accompanying condensed unaudited consolidated financial statements
  have been prepared by Myriad Genetics, Inc. (the "Company") in
        accordance with generally accepted accounting principles for interim
  financial information and pursuant to the applicable rules and
        regulations of the Securities and Exchange Commission. The condensed
       unaudited consolidated financial statements include the accounts of
          the Company and its wholly-owned subsidiary. All material intercompany
       accounts and transactions have been eliminated in consolidation. In
    the opinion of management, the accompanying financial statements
         contain all adjustments (consisting of normal and recurring accruals)
       necessary to present fairly all financial statements. The financial
      statements herein should be read in conjunction with the Company's
       audited consolidated financial statements and notes thereto for the
     fiscal year ended June 30, 1996, included in the Company's Annual
   Report on Form 10-K for the year ended June 30, 1996. Operating
       results for the three-month period ended September 30, 1996 may not
         necessarily be indicative of the results to be expected for any other
interim period or for the full year.                        

6 

10-Q 7th Page of 13 TOC 1st Previous Next ↓Bottom Just 7th
MANAGEMENT'S DISCUSSION AND ANALYSIS  
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS  

Overview                                                                        

Since inception, the Company has devoted substantially all of its resources to  
maintaining its research and development programs, establishing a genetic       
testing laboratory, and supporting collaborative research agreements. To date,  
the Company has not received any revenues from the sale of products.  Revenues  
received by the Company primarily have been payments pursuant to collaborative  
research agreements.  The Company has been unprofitable since its inception and,
for the quarter ended September 30, 1996, the Company had a net loss of         
$2,830,079 and as of September 30, 1996 had an accumulated deficit of           
$17,771,191.                                                                    

In August 1995, the Company completed a three-year collaborative research and   
development agreement with Eli Lilly and Company to locate and sequence the     
BRCA1 breast and ovarian cancer gene. This agreement provided the Company with  
research funding and may in the future provide certain additional payments upon 
the attainment of research and regulatory milestones and royalty payments based 
on sales of any products resulting from the collaboration. The Company did not  
recognize revenue from this agreement during the quarter ended September 30,    
1996.                                                                           

In April 1995, the Company commenced a five-year collaborative research and     
development arrangement with Ciba-Geigy Corporation ("Ciba").  This             
collaboration provides the Company with an equity investment, research funding  
and potential milestone payments totalling $60,000,000.  The Company is entitled
to receive royalties from sales of therapeutic products sold by Ciba.  The      
Company recognized $1,085,069 in revenue under this agreement for the quarter   
ended September 30, 1996.                                                       

In September 1995, the Company commenced a five-year collaborative research and 
development arrangement with Bayer Corporation ("Bayer").  This collaboration   
provides the Company with an equity investment, research funding and potential  
milestone payments of up to $71,000,000.  The Company is entitled to receive    
royalties from sales of therapeutic products sold by Bayer.  The Company        
recognized $1,170,712 in revenue under this agreement for the quarter ended     
September 30, 1996.                                                             

The Company intends to enter into additional collaborative relationships to     
locate and sequence genes associated with other common diseases as well as      
continuing to fund internal research projects.  There can be no assurance that  
the Company will be able to enter into additional collaborative relationships on
terms acceptable to the Company.  The Company expects to incur losses for at    
least the next several years, primarily due to expansion of its research and    
development programs, increasing staffing costs and expansion of its facilities.
Additionally, the Company expects to incur substantial sales, marketing and     
other expenses in connection with launching its genetic predisposition testing  
business.  The Company expects that losses will fluctuate from quarter to       
quarter and that such fluctuations may be substantial.                          

The Company devoted significant resources during the quarter to the beta testing
and validation of the Company's BRACAnalysis/TM/ genetic predisposition test for
mutations of the BRCA1 and BRCA2 breast and ovarian cancer genes, as well as    
building its sales and marketing force in preparation for the commercial launch 
of the test.  The Company announced the commercial launch of BRACAnalysis/TM/ on
October 30, 1996.  There can be no assurance that the Company will succeed in   
achieving market acceptance for the BRACAnalysis/TM/ test.                      

Results of Operations                                                           

Three Months Ended September 30, 1996 and 1995                                  

Research revenues for the quarter ended September 30, 1996 increased $1,182,881 
from the same quarter of 1995. The increase was attributable to a full quarter  
of both the Ciba and Bayer research collaboration agreements providing ongoing  
research funding in 1996.  For the first fiscal quarter in 1995, both research  
collaboration agreements were in their start-up phase.  Research revenue from   
the research collaboration agreements is recognized as related costs are        
incurred.                                                                       

7 

10-Q 8th Page of 13 TOC 1st Previous Next ↓Bottom Just 8th
Research and development expenses for the quarter ended September 30, 1996      
increased to $4,094,743 from $2,381,159 for the same quarter of 1995.  This     
increase was primarily due to an increase in third party research programs      
funded by the Company, increased depreciation charges due to the purchase of    
additional equipment, the hiring of additional personnel and the increased use  
of laboratory supplies and reagents to meet the demands of the additional       
research collaboration agreements.  The Company also incurred increased         
development expenses during the quarter related to the beta testing and         
validation of the Company's BRACAnalysis/TM/ genetic predisposition test for    
mutations of the BRCA1 and BRCA2 breast and ovarian cancer genes.  When the     
BRCA1 and BRCA2 test moves from the development stage to production, the Company
expects research and development expenses to decrease as expenses related to the
test are classified as cost of sales.  There can be no assurance that the       
Company will be able to produce the test in a timely fashion or at acceptable   
quality levels and prices.                                                      

Selling, general and administrative expenses for the quarter ended September 30,
1996 increased $1,351,773 from the same quarter of 1995.  The increase was      
attributable to additional administrative, marketing and education personnel,   
market research activities, education material development, facilities-related  
costs and deferred compensation related to grants of stock options and warrants.
The Company expects its general and administrative expenses will continue to    
increase in support of its research and development efforts and genetic         
predisposition testing business.                                                

Interest income for the quarter ended September 30, 1996 increased to $848,494  
from $275,223 for the same quarter of 1995.  This increase was primarily due to 
the increased funds available for investment, which funds were raised in the    
Company's initial public offering in October 1995, and in connection with       
entering into the Company's research and development collaborations with Ciba   
and Bayer in April 1995 and September 1995, respectively.  Interest expense for 
the quarter ended September 30, 1996, amounting to $19,652, was due entirely to 
borrowings under the Company's equipment financing facility, which are secured  
by equipment and have a repayment term of 48 months from the date of funding.   
The net loss increased to $2,830,079 for the quarter ended September 30, 1996   
from $1,602,903 for the same quarter in 1995.                                   

Liquidity and Capital Resources                                                 

Net cash used in operating activities was $1,573,201 during the quarter ended   
September 30, 1996 and $1,525,535 during the same quarter of 1995.  Non-trade   
receivables decreased $62,079 between June 30, 1996 and September 30, 1996      
primarily as a result of the write-off an uncollectable receivable.  Accounts   
payable and accrued expenses increased $461,839 between June 30, 1996 and       
September 30, 1996 as a result of the Company's purchase during the quarter of  
equipment to be installed in the Company's new genetic testing facility.        

The Company's investing activities provided cash of $3,230,329 in the three     
months ended September 30, 1996 and used cash of $13,099,006 in the three months
ended September 30, 1995.  Investing activities in the quarter ended September  
30, 1996 were comprised primarily of capital expenditures for research          
equipment, office furniture, and facility improvements and reinvestment of      
marketable investment securities from long-term investments to short-term cash  
equivalents.  During the quarter ended September 30, 1995, the Company had      
shifted its investment in marketable securities from short-term cash equivalents
to long-term investments.                                                       

Financing activities used $48,228 during the quarter ended September 30, 1996.  
The Company reduced the principal on its equipment financing facility by        
$74,186.  This decrease was offset by proceeds of $25,958 from the exercise of  
stock options.  Financing activities provided $9,915,930 during the quarter     
ended September 30, 1995.  The Company reduced the principal on its equipment   
financing facility by $66,793 and received an equity investment of approximately
$10,000,000 from Bayer during that time.                                        

The Company anticipates that its existing capital resources, including the net  
proceeds of its initial public offering and interest earned thereon, will be    
adequate to maintain its current and planned operations for at least the next   
two years, although no assurance can be given that changes will not occur that  
would consume available capital resources before such time.  The Company's      
future capital requirements will be substantial and will depend on many factors,
including progress of the Company's research and development programs, the      
results and cost of clinical correlation testing of the Company's genetic tests,
the costs of filing, prosecuting and enforcing patent claims, competing         

8 

10-Q 9th Page of 13 TOC 1st Previous Next ↓Bottom Just 9th
technological and market developments, payments received under collaborative    
agreements, changes in collaborative research relationships, the costs          
associated with potential commercialization of its gene discoveries, if any,    
including the development of manufacturing, marketing and sales capabilities,   
the cost and availability of third-party financing for capital expenditures and 
administrative and legal expenses.  Because of the Company's significant long-  
term capital requirements, the Company intends to raise funds when conditions   
are favorable, even if it does not have an immediate need for additional capital
at such time.                                                                   

Certain Factors That May Affect Future Results of Operations                    

The Company believes that this report on Form 10-Q contains certain forward-    
looking statements as that term is defined in the Private Securities Litigation 
Reform Act of 1995.  Such statements are based on management's current          
expectations and are subject to a number of factors and uncertainties which     
could cause actual results to differ materially from those described in the     
forward-looking statements.  The Company cautions investors that there can be no
assurance that actual results or business conditions will not differ materially 
from those projected or suggested in such forward-looking statements as a result
of various factors, including, but not limited to, the following: intense       
competition related to the discovery of disease-related genes and the           
possibility that others may discover, and the Company may not be able to gain   
rights with respect to, genes important to the establishment of a successful    
genetic testing business, difficulties inherent in developing genetic tests once
genes have been discovered; the Company's limited experience in developing a    
genetic testing laboratory; the Company's limited marketing and sales experience
and the risk that any tests which the Company develops may not be able to be    
marketed at acceptable prices or receive commercial acceptance in the markets   
that the Company expects to target; uncertainty as to whether there will exist  
adequate reimbursement for the Company's services from government, private      
healthcare insurers and third-party payors; and uncertainties as to the extent  
of future government regulation of the Company's business.  As a result, the    
Company's future development efforts involve a high degree of risk.  For further
information, refer to the more specific risks and uncertainties disclosed       
throughout this Quarterly Report on Form 10-Q.                                  

9 

10-Q 10th Page of 13 TOC 1st Previous Next ↓Bottom Just 10th
PART II - Other Information 

Item 1.   Legal Proceedings.                                                    

The Company is not a party to any litigation in any court, and management is not
aware of any contemplated proceeding by any governmental authority against the  
Company.                                                                        

Item 2.   Changes in Securities.                                                

None.                                                                           

Item 3.   Defaults Upon Senior Securities.                                      

None.                                                                           

Item 4.   Submission of Matters to a Vote of Security Holders.                  

None.                                                                           

Item 5.   Other Information.                                                    

None.                                                                           

Item 6.   Exhibits and Reports on Form 8-K.                                     

(a)  Exhibits                                                                   
--------                                                              
 The following is a list of exhibits filed as part of this Quarterly
Report on Form 10-Q.                                                            

Exhibit                                                                         
Number      Description                                                         
------      -----------                                                         

10.1        Patent and Technology License Agreement dated September 26, 1996    
         among the Board of Regents of The University of Texas System, The
            University of Texas M.D. Anderson Cancer Center and the Company. The
          Company has excluded from this Exhibit 10.1 portions of the Patent
            and Technology License Agreement for which the Company has requested
           confidential treatment from the Securities and Exchange Commission.
       The portions of the Patent and Technology License Agreement for
            which confidential treatment has been requested are marked "[ ]" and
      such confidential portions have been filed separately with the
Securities and Exchange Commission.                     

10.2        Lease Agreement, dated October 12, 1995, between The Boyer Research 
        Park Associates V, by its general partner, The Boyer Company and
the Company.                                            

10.3        Amendment to Lease Agreement, dated March 29, 1996, between The     
           Boyer Research Park Associates V, by its general partner, The Boyer
Company and the Company.                                

10.4        Letter Agreement, dated March 4, 1996, among The University of Utah,
            Genetic Epidemiology and the Company regarding Extension of Standard
            Research Agreement and Form of License Agreement between the Company
         and The University of Utah, effective January 1, 1993, as amended
         (Genes Predisposing to Cancer). The Company has omitted from this
           Exhibit 10.4 portions of the Letter Agreement for which the Company
    has requested confidential treatment from the Securities and
           Exchange Commission. The portions of the Letter Agreement for which
           confidential treatment has been requested are marked "[ ]" and such
            confidential portions have been filed separately with the Securities
and Exchange Commission.                                

10

10-Q 11th Page of 13 TOC 1st Previous Next ↓Bottom Just 11th
11.1        Statement Regarding Computation of Net Loss Per Share               

27.1        Financial Data Schedule                                             

(b)  Reports on Form 8-K                                                        
-------------------                                                   

No reports on Form 8-K were filed during the quarter ended September 30, 1996.  

11

10-Q 12th Page of 13 TOC 1st Previous Next ↓Bottom Just 12th
SIGNATURES  

Pursuant to the requirements of the Securities Exchange Act of 1934, the        
Registrant has duly caused this report to be signed on its behalf by the        
undersigned thereunto duly authorized.                                          

       MYRIAD GENETICS, INC.

Date: November 8, 1996              By: /s/ Peter D. Meldrum                    
----------------              --------------------------            
  Peter D. Meldrum
                       President and Chief Executive Officer

Date: November 8, 1996            /s/ Jay M. Moyes                              
----------------            ---------------------------             
Jay M. Moyes  
           Vice President of Finance
                              (principal financial and accounting officer)

12

10-Q Last Page of 13 TOC 1st Previous Next ↓Bottom Just 13th
MYRIAD GENETICS, INC. 

EXHIBIT INDEX 

Exhibit                                                                         
Number      Description                                                         
------      -----------                                                         

10.1        Patent and Technology License Agreement dated September 26, 1996    
         among the Board of Regents of The University of Texas System, The
            University of Texas M.D. Anderson Cancer Center and the Company. The
          Company has excluded from this Exhibit 10.1 portions of the Patent
            and Technology License Agreement for which the Company has requested
           confidential treatment from the Securities and Exchange Commission.
       The portions of the Patent and Technology License Agreement for
            which confidential treatment has been requested are marked "[ ]" and
      such confidential portions have been filed separately with the
Securities and Exchange Commission.                     

10.2        Lease Agreement, dated October 12, 1995, between The Boyer Research 
         Park Associates V, by its general partner, The Boyer Company L.P.
and the Company.                                        

10.3        Amendment to Lease Agreement, dated March 29, 1996, between The     
           Boyer Research Park Associates V, by its general partner, The Boyer
Company L.P. and the Company.                           

10.4        Letter Agreement, dated March 4, 1996, among The University of Utah,
            Genetic Epidemiology and the Company regarding Extension of Standard
            Research Agreement and Form of License Agreement between the Company
         and The University of Utah, effective January 1, 1993, as amended
         (Genes Predisposing to Cancer). The Company has omitted from this
           Exhibit 10.4 portions of the Letter Agreement for which the Company
    has requested confidential treatment from the Securities and
           Exchange Commission. The portions of the Letter Agreement for which
           confidential treatment has been requested are marked "[ ]" and such
            confidential portions have been filed separately with the Securities
and Exchange Commission.                                

11.1        Statement Regarding Computation of Net Loss Per Share               

27.1        Financial Data Schedule                                             

13

10-Q	1st Page of 13	TOC	↑Top	Previous	Next	↓Bottom	Just 1st

10-Q	2nd Page of 13	TOC	1st	Previous	Next	↓Bottom	Just 2nd

10-Q	3rd Page of 13	TOC	1st	Previous	Next	↓Bottom	Just 3rd

10-Q	4th Page of 13	TOC	1st	Previous	Next	↓Bottom	Just 4th

10-Q	5th Page of 13	TOC	1st	Previous	Next	↓Bottom	Just 5th

10-Q	6th Page of 13	TOC	1st	Previous	Next	↓Bottom	Just 6th

10-Q	7th Page of 13	TOC	1st	Previous	Next	↓Bottom	Just 7th

10-Q	8th Page of 13	TOC	1st	Previous	Next	↓Bottom	Just 8th

10-Q	9th Page of 13	TOC	1st	Previous	Next	↓Bottom	Just 9th

10-Q	10th Page of 13	TOC	1st	Previous	Next	↓Bottom	Just 10th

10-Q	11th Page of 13	TOC	1st	Previous	Next	↓Bottom	Just 11th

10-Q	12th Page of 13	TOC	1st	Previous	Next	↓Bottom	Just 12th

10-Q	Last Page of 13	TOC	1st	Previous	Next	↓Bottom	Just 13th

Dates Referenced Herein and Documents Incorporated by Reference

		Referenced-On Page
This ‘10-Q’ Filing	Date	First	Last	Other Filings

	9/15/97
Filed on:	11/8/96	12
	11/5/96	1
	10/30/96	7
For Period End:	9/30/96	1	11	10-Q/A
	9/26/96	10	13
	6/30/96	3	8
	3/29/96	10	13
	3/4/96	10	13
	10/12/95	10	13
	9/30/95	2	8
	1/1/93	10	13
				List all Filings

5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/28/24  Myriad Genetics Inc.              10-K       12/31/23  127:39M
 3/01/23  Myriad Genetics Inc.              10-K       12/31/22  113:13M
 2/25/22  Myriad Genetics Inc.              10-K       12/31/21  116:13M
 3/16/21  Myriad Genetics Inc.              10-KT      12/31/20  128:16M
 8/13/20  Myriad Genetics Inc.              10-K        6/30/20  122:21M                                    ActiveDisclosure/FA

↑Top

Filing Submission 0000927016-96-001627 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Myriad Genetics Inc – ‘10-Q’ for 9/30/96

As of: Friday, 11/8/96 · For: 9/30/96 · Accession #: 927016-96-1627 · File #: 0-26642

Quarterly Report — Form 10-QFiling Table of Contents

10-Q — Quarterly ReportDocument Table of Contents

Dates Referenced Herein and Documents Incorporated by Reference

5 Subsequent Filings that Reference this Filing

Quarterly Report — Form 10-Q
Filing Table of Contents

10-Q — Quarterly Report
Document Table of Contents